Preemptive treatment with voriconazole in lung transplant recipients

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 344-353

  Neoh, C F ^a,b   Snell, G I ^a   Levvey, B ^a   Kotsimbos, T ^a   Morrissey, C O ^a   Slavin, M A ^a,c   Stewart, K ^a   Kong, D C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b University of Technology Mara Penang   (Malaysia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Antifungal; Lung transplant; Post transplant infection; Preemptive; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; EVEROLIMUS; GANCICLOVIR; HYPERIMMUNE GLOBULIN; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ARTICLE; ASPERGILLOMA; ASPERGILLUS FUMIGATUS; BACKACHE; BILIRUBIN BLOOD LEVEL; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS ISOLATION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT INFECTION; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

EID: 84880808573     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12071     Document Type: Article

References (51)

1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8): 1101-1111.
2. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4): S180-S191.
3. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (3): 220-229.
4. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61 (6): 915-919.
5. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112 (5): 1160-1164.
6. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123 (3): 800-808.
7. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9 (8): 1903-1911.
8. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11 (5): 359-365.
9. Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect 2002; 17 (4): 291-302.
10. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3): 753-755.
11. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20 (12): 1274-1281.
12. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int 2007; 20 (12): 993-1015.
13. Sole A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008; 22 (2): 89-104.
14. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5 (1): 26-34.
15. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; (3): CD004291.
16. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9 (9): 2085-2091.
17. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation 2004; 77(2): 232-237.
18. Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007; 9 (2): 121-125.
19. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation - a world-wide survey. Am J Transplant 2011; 11 (2): 361-366.
20. Snell GI, Esmore DS, Westall GP, et al. The Alfred Hospital lung transplant experience. Clin Transpl 2007; 131-144.
21. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26 (12): 1229-1242.
22. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
23. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67 (2): 132-143.
24. Micromedex® Healthcare Series. DRUGDEX System. Availble at: http://www.thomsonhc.com/hcs/librarian (accessed 12 July 2011).
25. Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30 (4): 361-374.
26. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl. 1): S207-S238.
27. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6): 408-415.
28. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354 (7): 731-739.
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-245.
30. Hosseini SM, Singer L, Chapparo C, et al. Is targeted antifungal prophylaxis effective in lung transplants? (abstract). J Heart Lung Transplant 2010; 29 (2, Suppl. 1): S186.
31. Mattner F, Fischer S, Weissbrodt H, et al. Effect of antimycotic prophylaxis with itraconazole and voriconazole in patients following lung transplantation (abstract). J Heart Lung Transplant 2006; 25 (2, Suppl. 1): S105.
32. Wearmouth DA, Rennison C, Fisher A, Lordan J, Corris PA, Gould FK. Effectiveness of targeted pro-active management of Aspergillus fumigatus infections before and after lung transplantation (abstract). J Heart Lung Transplant 2009; 28 (2, Suppl. 1): S289.
33. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6 (12): 3008-3016.
34. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26 (12): 879-886.
35. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical Approach to Infections in the Compromised Host. (3rd edn.) New York: Plenum, 1994: 629-705.
36. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
37. Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26 (7): 681-686.
38. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26 (8): 782-795.
39. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29 (10): 1104-1118.
40. Fungal infections. Am J Transplant 2004; 4 (Suppl. 10): 110-134.
41. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39 (Suppl. 4): S200-S206.
42. Magill SS, Dropulic LK. Antifungal prophylaxis in transplant recipients: where do we go from here? Transpl Infect Dis 2006; 8 (4): 187-189.
43. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004; 36 (4): 312-314.
44. Vfend (voriconazole) package insert. New York: Pfizer, Inc, 2008.
45. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46 (2): 235-243.
46. Lehneman JB, Smallwood GA, Lesniak LA, Lawrence EC. Review of patient outcomes of Aspergillus prophylaxis with voriconazole after lung transplantation (abstract). J Heart Lung Transplant 2005; 24 (2, Suppl. 1): S169.
47. Clancy C, Celik U, Vadnerkar A, Nguyen M. Mortality due to invasive fungal infections is low in lung transplant recipients receiving voriconazole prophylaxis (abstract). Clin Microbiol Infect 2011; 17 (Suppl. 4): S34.
48. Beck CA, Chambers DC, Kermeen FD, Tse T, Hopkins PMA. Significant side effect burden of voriconazole curtails clinical utility in lung transplantation (abstract). J Heart Lung Transplant 2010; 29 (2, Suppl.): S138-S139.
49. Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity in lung transplant recipients (abstract). J Heart Lung Transplant 2011; 30 (4, Suppl. 1): S147.
50. Hussaini T, Ruping MJ, Farowski F, Vehreschild JJ, Cornely OA. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011; 31 (2): 214-225.
51. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010; 31 (2): 222-233.